Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation
© 2016, American Society for Microbiology. All Rights Reserved. A rapid decline in the development of new antimicrobial therapeutics has coincided with the emergence of new and more aggressive multidrug-resistant pathogens. Pathogens are protected from antibiotic activity by their ability to enter a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
American Society for Microbiology
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/7404 |
| _version_ | 1848745358699528192 |
|---|---|
| author | Reen, F. Phelan, J. Gallagher, L. Woods, D. Shanahan, R. Cano, R. Muimhneacháin, E. McGlacken, G. O'Gara, Fergal |
| author_facet | Reen, F. Phelan, J. Gallagher, L. Woods, D. Shanahan, R. Cano, R. Muimhneacháin, E. McGlacken, G. O'Gara, Fergal |
| author_sort | Reen, F. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2016, American Society for Microbiology. All Rights Reserved. A rapid decline in the development of new antimicrobial therapeutics has coincided with the emergence of new and more aggressive multidrug-resistant pathogens. Pathogens are protected from antibiotic activity by their ability to enter an aggregative biofilm state. Therefore, disrupting this process in pathogens is a key strategy for the development of next-generation antimicrobials. Here, we present a suite of compounds, based on the Pseudomonas aeruginosa 2-heptyl-4(1H)-quinolone (HHQ) core quinolone interkingdom signal structure, that exhibit noncytotoxic antibiofilm activity toward the fungal pathogen Candida albicans. In addition to providing new insights into what is a clinically important bacterium-fungus interaction, the capacity to modularize the functionality of the quinolone signals is an important advance in harnessing the therapeutic potential of signaling molecules in general. This provides a platform for the development of potent next-generation small-molecule therapeutics targeting clinically relevant fungal pathogens. |
| first_indexed | 2025-11-14T06:16:06Z |
| format | Journal Article |
| id | curtin-20.500.11937-7404 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:16:06Z |
| publishDate | 2016 |
| publisher | American Society for Microbiology |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-74042023-02-22T06:24:15Z Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation Reen, F. Phelan, J. Gallagher, L. Woods, D. Shanahan, R. Cano, R. Muimhneacháin, E. McGlacken, G. O'Gara, Fergal © 2016, American Society for Microbiology. All Rights Reserved. A rapid decline in the development of new antimicrobial therapeutics has coincided with the emergence of new and more aggressive multidrug-resistant pathogens. Pathogens are protected from antibiotic activity by their ability to enter an aggregative biofilm state. Therefore, disrupting this process in pathogens is a key strategy for the development of next-generation antimicrobials. Here, we present a suite of compounds, based on the Pseudomonas aeruginosa 2-heptyl-4(1H)-quinolone (HHQ) core quinolone interkingdom signal structure, that exhibit noncytotoxic antibiofilm activity toward the fungal pathogen Candida albicans. In addition to providing new insights into what is a clinically important bacterium-fungus interaction, the capacity to modularize the functionality of the quinolone signals is an important advance in harnessing the therapeutic potential of signaling molecules in general. This provides a platform for the development of potent next-generation small-molecule therapeutics targeting clinically relevant fungal pathogens. 2016 Journal Article http://hdl.handle.net/20.500.11937/7404 10.1128/AAC.00190-16 American Society for Microbiology unknown |
| spellingShingle | Reen, F. Phelan, J. Gallagher, L. Woods, D. Shanahan, R. Cano, R. Muimhneacháin, E. McGlacken, G. O'Gara, Fergal Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title | Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title_full | Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title_fullStr | Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title_full_unstemmed | Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title_short | Exploiting interkingdom interactions for development of small-molecule inhibitors of Candida albicans biofilm formation |
| title_sort | exploiting interkingdom interactions for development of small-molecule inhibitors of candida albicans biofilm formation |
| url | http://hdl.handle.net/20.500.11937/7404 |